BR112017015448A2 - derivados de benzamida de tetrahidropiranila - Google Patents
derivados de benzamida de tetrahidropiranilaInfo
- Publication number
- BR112017015448A2 BR112017015448A2 BR112017015448A BR112017015448A BR112017015448A2 BR 112017015448 A2 BR112017015448 A2 BR 112017015448A2 BR 112017015448 A BR112017015448 A BR 112017015448A BR 112017015448 A BR112017015448 A BR 112017015448A BR 112017015448 A2 BR112017015448 A2 BR 112017015448A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- present
- tetrahydropyranyl
- benzamide derivatives
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
Abstract
a presente invenção refere-se aos compostos da fórmula abaixo em que r, r1-r3 são como descritos na presente invenção; métodos de tratamento de pacientes para diabetes usando os compostos e processos para a preparação dos compostos. a presente invenção refere-se aos compostos da fórmula abaixo em que r, r1-r3 são como descritos na presente invenção; métodos de tratamento de pacientes para diabetes usando os compostos e processos para a preparação dos compostos. a presente invenção refere-se aos compostos da fórmula abaixo em que r, r1-r3 são como descritos na presente invenção; métodos de tratamento de pacientes para diabetes usando os compostos e processos para a preparação dos compostos. a presente invenção refere-se aos compostos da fórmula abaixo em que r, r1-r3 são como descritos na presente invenção; métodos de tratamento de pacientes para diabetes usando os compostos e processos para a preparação dos compostos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2015/073563 WO2016138631A1 (en) | 2015-03-03 | 2015-03-03 | Imidazo benzamide compounds |
| PCT/CN2016/074083 WO2016138821A1 (en) | 2015-03-03 | 2016-02-19 | Tetrahydropyranyl benzamide derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017015448A2 true BR112017015448A2 (pt) | 2018-01-30 |
Family
ID=56849060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017015448A BR112017015448A2 (pt) | 2015-03-03 | 2016-02-19 | derivados de benzamida de tetrahidropiranila |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10196385B2 (pt) |
| EP (1) | EP3265460A4 (pt) |
| JP (1) | JP2018507232A (pt) |
| KR (1) | KR20170106483A (pt) |
| CN (1) | CN107406436B (pt) |
| AU (1) | AU2016228055B2 (pt) |
| BR (1) | BR112017015448A2 (pt) |
| CA (1) | CA2975413A1 (pt) |
| CL (1) | CL2017002148A1 (pt) |
| CO (1) | CO2017008721A2 (pt) |
| CR (1) | CR20170354A (pt) |
| DO (1) | DOP2017000196A (pt) |
| EA (1) | EA201791745A1 (pt) |
| EC (1) | ECSP17058071A (pt) |
| IL (1) | IL253405A0 (pt) |
| MA (1) | MA41641A (pt) |
| MX (1) | MX2017011087A (pt) |
| PE (1) | PE20171650A1 (pt) |
| PH (1) | PH12017501560A1 (pt) |
| SG (1) | SG11201706718RA (pt) |
| SV (1) | SV2017005520A (pt) |
| TN (1) | TN2017000372A1 (pt) |
| WO (2) | WO2016138631A1 (pt) |
| ZA (1) | ZA201704948B (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018014337A1 (en) * | 2016-07-22 | 2018-01-25 | Eli Lilly And Company | 3-Chloro-N- [ (1R, 3S) -3- [5- (3, 5-dimethylimidazol-4-yl) -4H-1, 2, 4-triazol-3-yl] cyclohexyl] -N-methyl-benzamide |
| CN111902413B (zh) | 2018-03-09 | 2023-10-17 | 里科瑞尔姆Ip控股有限责任公司 | 取代的1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010505957A (ja) | 2006-10-10 | 2010-02-25 | アムゲン インコーポレイティッド | 糖尿病に対して使用されるｎ−アリールピラゾール化合物 |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| JP5685181B2 (ja) * | 2009-03-05 | 2015-03-18 | 塩野義製薬株式会社 | Ｎｐｙｙ５受容体拮抗作用を有するシクロヘキサン誘導体 |
| EP2523558A4 (en) * | 2010-01-15 | 2013-06-19 | Merck Sharp & Dohme | BETA-CARBOLINE OXADIAZOLE DERIVATIVES AS ANTIDIABETIC COMPOUNDS |
| WO2012123449A1 (en) * | 2011-03-14 | 2012-09-20 | Boehringer Ingelheim International Gmbh | N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators |
| WO2015120610A1 (en) | 2014-02-14 | 2015-08-20 | Eli Lilly And Company | Gpr142 agonist compound |
-
2015
- 2015-03-03 WO PCT/CN2015/073563 patent/WO2016138631A1/en active Application Filing
-
2016
- 2016-02-18 MA MA041641A patent/MA41641A/fr unknown
- 2016-02-19 CR CR20170354A patent/CR20170354A/es unknown
- 2016-02-19 US US15/118,295 patent/US10196385B2/en active Active
- 2016-02-19 JP JP2017546161A patent/JP2018507232A/ja active Pending
- 2016-02-19 MX MX2017011087A patent/MX2017011087A/es unknown
- 2016-02-19 BR BR112017015448A patent/BR112017015448A2/pt not_active IP Right Cessation
- 2016-02-19 PE PE2017001456A patent/PE20171650A1/es not_active Application Discontinuation
- 2016-02-19 WO PCT/CN2016/074083 patent/WO2016138821A1/en active Application Filing
- 2016-02-19 AU AU2016228055A patent/AU2016228055B2/en not_active Expired - Fee Related
- 2016-02-19 CN CN201680013049.8A patent/CN107406436B/zh active Active
- 2016-02-19 EP EP16758437.4A patent/EP3265460A4/en not_active Withdrawn
- 2016-02-19 TN TNP/2017/000372A patent/TN2017000372A1/en unknown
- 2016-02-19 EA EA201791745A patent/EA201791745A1/ru unknown
- 2016-02-19 SG SG11201706718RA patent/SG11201706718RA/en unknown
- 2016-02-19 KR KR1020177024303A patent/KR20170106483A/ko not_active Application Discontinuation
- 2016-02-19 CA CA2975413A patent/CA2975413A1/en not_active Abandoned
-
2017
- 2017-07-10 IL IL253405A patent/IL253405A0/en unknown
- 2017-07-20 ZA ZA2017/04948A patent/ZA201704948B/en unknown
- 2017-08-21 DO DO2017000196A patent/DOP2017000196A/es unknown
- 2017-08-22 SV SV2017005520A patent/SV2017005520A/es unknown
- 2017-08-23 CL CL2017002148A patent/CL2017002148A1/es unknown
- 2017-08-28 CO CONC2017/0008721A patent/CO2017008721A2/es unknown
- 2017-08-30 PH PH12017501560A patent/PH12017501560A1/en unknown
- 2017-09-01 EC ECIEPI201758071A patent/ECSP17058071A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12017501560A1 (en) | 2018-02-05 |
| CO2017008721A2 (es) | 2018-01-05 |
| AU2016228055B2 (en) | 2018-06-07 |
| KR20170106483A (ko) | 2017-09-20 |
| TN2017000372A1 (en) | 2019-01-16 |
| CN107406436A (zh) | 2017-11-28 |
| PE20171650A1 (es) | 2017-11-13 |
| IL253405A0 (en) | 2017-09-28 |
| EP3265460A1 (en) | 2018-01-10 |
| US20180194755A1 (en) | 2018-07-12 |
| MX2017011087A (es) | 2017-11-10 |
| EP3265460A4 (en) | 2018-08-08 |
| JP2018507232A (ja) | 2018-03-15 |
| DOP2017000196A (es) | 2017-09-15 |
| CA2975413A1 (en) | 2016-09-09 |
| CR20170354A (es) | 2017-09-05 |
| WO2016138631A1 (en) | 2016-09-09 |
| ECSP17058071A (es) | 2017-10-31 |
| SV2017005520A (es) | 2018-08-27 |
| SG11201706718RA (en) | 2017-09-28 |
| ZA201704948B (en) | 2019-02-27 |
| US10196385B2 (en) | 2019-02-05 |
| EA201791745A1 (ru) | 2018-01-31 |
| CL2017002148A1 (es) | 2018-04-13 |
| AU2016228055A1 (en) | 2017-08-17 |
| WO2016138821A1 (en) | 2016-09-09 |
| MA41641A (fr) | 2018-01-09 |
| CN107406436B (zh) | 2021-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018001400A2 (pt) | compostos, processo para a síntese dos compostos, composição, utilização de um composto, método para o combate dos fungos e sementes | |
| BR112017027414A2 (pt) | Derivados hidroxiéster, processo para prepará- los e composições farmacêuticas os contendo | |
| BR112016014020A8 (pt) | moduladores de tetra-hidropiridopirazinas de gpr6. | |
| BR112017009701A2 (pt) | composto e métodos para a preparação de um composto | |
| BR112017028318A2 (pt) | compostos antibacterianos | |
| BR112017007123A2 (pt) | derivados de tetrahidroisoquinolina | |
| BR112018005194A2 (pt) | processo de composto antifúngico | |
| BR112015017606A2 (pt) | composição, método de produzir a composição, utilização da composição e combustível obtido a partir da composição | |
| BR112017004741A2 (pt) | compostos e composições como inibidores da raf quinase | |
| BR112018012112A2 (pt) | heteroaril-hidroxipirimidinonas como agonistas do receptor apj | |
| BR112018075939A2 (pt) | compostos heterocíclicos como antibacterianos | |
| BR112016028476A8 (pt) | compostos, composição, uso de um composto e método para o combate dos fungos nocivos | |
| BR112018011969A2 (pt) | compostos heteroaromáticos como inibidores de btk | |
| BR112016007396A2 (pt) | derivados de cetona pirídicos, método de preparação dos mesmos e aplicação farmacêutica dos mesmos | |
| BR112018010140A8 (pt) | compostos de fórmula, composição, utilização de um composto de fórmula, método para o combate de fungos fitopatogênicos e semente | |
| BR112016021282A8 (pt) | processos para a preparação de compostos antifúngicos e os referidos compostos | |
| BR112016011734A2 (pt) | Indóis substituídos e funcionalizados como agentes anti-câncer | |
| DOP2017000064A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| CL2014002661A1 (es) | Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer. | |
| BR112018010316A2 (pt) | compostos de fórmula, composição, utilização de um composto de fórmula, método para o combate de fungos fitopatogênicos e semente | |
| BR112017018305A2 (pt) | desacetoxitubulisina h e análogos da mesma | |
| BR112017000821A2 (pt) | novos compostos de pirimidina substituída. | |
| BR112018006519A2 (pt) | compostos de fórmula, processo para a síntese de compostos, compostos intermediários x, composição, utilização de um composto de fórmula, método para o combate de fungos e semente | |
| BR112017010645A2 (pt) | derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos | |
| BR112015014583B1 (pt) | compostos, processo para a preparação de compostos, compostos intermediários, composição, usos de um composto de fórmula i e método para combater fungos nocivos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2554 DE 17/12/2019. |